SU1258414A1 - Method of treatment of patients ill with dysentery - Google Patents

Method of treatment of patients ill with dysentery Download PDF

Info

Publication number
SU1258414A1
SU1258414A1 SU833654141A SU3654141A SU1258414A1 SU 1258414 A1 SU1258414 A1 SU 1258414A1 SU 833654141 A SU833654141 A SU 833654141A SU 3654141 A SU3654141 A SU 3654141A SU 1258414 A1 SU1258414 A1 SU 1258414A1
Authority
SU
USSR - Soviet Union
Prior art keywords
treatment
dysentery
patients
furazolidone
patients ill
Prior art date
Application number
SU833654141A
Other languages
Russian (ru)
Inventor
Федор Андреевич Туманов
Лия Павловна Юрко
Алан Харитонович Кайтмазов
Галина Ивановна Гончарова
Элеонора Петровна Козлова
Алла Михайловна Лянная
Original Assignee
Центральный научно-исследовательский институт эпидемиологии
Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Центральный научно-исследовательский институт эпидемиологии, Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского filed Critical Центральный научно-исследовательский институт эпидемиологии
Priority to SU833654141A priority Critical patent/SU1258414A1/en
Application granted granted Critical
Publication of SU1258414A1 publication Critical patent/SU1258414A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Description

ii

Изобретение относитс  к медицине в частности к лечению больных дизентерией .The invention relates to medicine, in particular, to the treatment of patients with dysentery.

Цель изобретени  - сокращение сроков лечени .The purpose of the invention is to reduce the duration of treatment.

Пример 1, Предлагаемый способ лечени  применен у 82 больных дизентерией. Больному назначают фура золидон в дозе 0,1 г 4 раза в сутки в течение 2-5 дней до прекращени  диареи, при зтом больной одновременно получает бифидосодержащий кисломолочный продукт по 150-200 мл 2 раза в день в течение не менее 5-7 дней. Больным с сохранившимс  выраженным дисбактериозом кишечника после 5-7 дневного курса лечени  молочным бифидумбактерином данный препарат назна чаетс  еще в течение 2-3 дней.Example 1 The proposed method of treatment is applied in 82 patients with dysentery. A patient is prescribed a fura-zolidone in a dose of 0.1 g 4 times a day for 2-5 days before stopping diarrhea, with this patient simultaneously receiving a bifido-containing fermented milk product of 150-200 ml 2 times a day for at least 5-7 days. Patients with preserved severe intestinal dysbiosis after a 5–7 day course of treatment with milk bifidumbacterin are given this drug for a further 2–3 days.

4,0+0,154.0 + 0.15

4,4±0,16 PiO,024.4 ± 0.16 PiO, 02

4,OiO,224, OiO, 22

4,5tO,M ,024,5tO, M, 02

4,liO,134, liO, 13

4,5tO,28 4,5tO,24 9,4 ,0i4,5tO, 28 4,5tO, 24 9.4, 0i

5,510,11 6,6+0,12 15,45.510.11 6.6 + 0.12 15.4

,ooi;, ooi;

4,9±0,13 5,3tO,15 12,54.9 ± 0.13 5.3 tO, 15 12.5

Примечание.Note.

P дано в сравнении с группой больных, лечившихс  фуразолидоном.P is given in comparison with the group of patients treated with furazolidone.

ВНИИПИVNIIPI

Заказ 5052/4Order 5052/4

Произв.-полигр. , г. жгород, ул. Проектна , 4Random polygons , zhgorod, st. Project, 4

584142584142

При сопоставлении предложенной схемы лечени  с другими способами лечени  наилучший эффект отмечен в группе больных, получавших молочныйWhen comparing the proposed treatment regimen with other methods of treatment, the best effect was observed in the group of patients who received milk

5 бифидумбактерин в сочетании с фура- золидоном; достоверное уменьшение продолжительности диареи, болезненности толстого кишечника и снижение частоты вы влени  выраженного вос 0 палИтельного процесса в кишечнике по данным ректороманоскопии, У больных , получавших только молочный бифидумбактерин , результаты лечени  были несколько лучшими, чем у боль15 ных, получавших фуразолидон. Менее выраженный эффект по всём показател м бып в группе больных, принимавших тетрациклин.5 Bifidumbacterin in combination with Furazolidone; a significant decrease in the duration of diarrhea, large intestine soreness and a reduction in the incidence of severe peritoneal inflammation in the intestine according to rectoromanoscopy. In patients who received only milk bifidumbacterin, the results of treatment were slightly better than in patients treated with furazolidone. A less pronounced effect in all indicators was in the group of patients taking tetracycline.

Эффективность разных методов ле20 чани  бопьных острой дизентерией приведена в таблице.The effectiveness of various methods of treatment of acute dysentery is given in the table.

6,96.9

30,6 ,00130.6, 001

56,2 89,2 79,856.2 89.2 79.8

Тираж fiftOCirculation fiftO

ПодписноеSubscription

Claims (1)

СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ДИЗЕНТЕРИЕЙ путем назначения фуразоли· дона с использованием бифидумбактерина, отличающийся тем, что, с целью сокращения сроков лечения, назначают бифидосодержащий кисломолочный продукт по 150-200 мп 2 раза в день в течение не менее 5-7 дней одновременно с фуразолидоном.METHOD FOR TREATING PATIENTS WITH DYSENTERY by prescribing furazolium-don using bifidumbacterin, characterized in that, in order to reduce treatment time, a bifid-containing fermented milk product is prescribed at 150-200 mp 2 times a day for at least 5-7 days simultaneously with furazolidone. ... SU 1258414 >... SU 1258414>
SU833654141A 1983-07-11 1983-07-11 Method of treatment of patients ill with dysentery SU1258414A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU833654141A SU1258414A1 (en) 1983-07-11 1983-07-11 Method of treatment of patients ill with dysentery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU833654141A SU1258414A1 (en) 1983-07-11 1983-07-11 Method of treatment of patients ill with dysentery

Publications (1)

Publication Number Publication Date
SU1258414A1 true SU1258414A1 (en) 1986-09-23

Family

ID=21086080

Family Applications (1)

Application Number Title Priority Date Filing Date
SU833654141A SU1258414A1 (en) 1983-07-11 1983-07-11 Method of treatment of patients ill with dysentery

Country Status (1)

Country Link
SU (1) SU1258414A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112006004066T5 (en) 2006-10-13 2009-08-20 Aleksandr Mettalinovich Tishin A magnetic carrier and medical preparation for controllably delivering and releasing drugs, methods of preparation thereof, and methods of treatment using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112006004066T5 (en) 2006-10-13 2009-08-20 Aleksandr Mettalinovich Tishin A magnetic carrier and medical preparation for controllably delivering and releasing drugs, methods of preparation thereof, and methods of treatment using the same

Similar Documents

Publication Publication Date Title
US5908838A (en) Method for the treatment of acne
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
US3008874A (en) Pharmaceutical compositions
SU1258414A1 (en) Method of treatment of patients ill with dysentery
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
US4150123A (en) Method for treating gastro intestinal ulcers with extract of herb cetraria
JPH0256420A (en) Memory disorder treatment drug containing aspartic acid and alginin
DE2528460A1 (en) 1-Carbamoyl 2-cyano aziridine as immunostimulant - for therapy of bacterial and viral infections
RU1826911C (en) Method of prophylaxis and treating atherosclerosis in experiment
SU1034741A1 (en) Tuberculosis treatment method
SU1517965A1 (en) Method of treatment of neurological symptoms of lumbar osteochondrosis
CN100553681C (en) A kind of Alficetin eye solution and preparation method thereof
SU1232257A1 (en) Method of treatment of pulmonary tuberculosis
SU1162433A1 (en) Method of treatment of children's glomerulonephritis
RU2071780C1 (en) Method of treatment of medicinal esophago-gingivo-stomatitis
Misra A comparative study of tinidazole and metronidazole as a single daily dose for three days in symptomatic intestinal amoebiasis
US4885288A (en) Pharmaceutical compositions containing lysine acetylsalicylate
US4073928A (en) Therapeutic treatment for viral regional ileitis infection
US3562388A (en) Treatment for mammals infected with pathogenic bacteria
Chunn et al. Experimental studies on alimentary azotemia: III. Site of blood absorption
RU2139099C1 (en) Method of treatment of angioneurotic edema
SU1163862A1 (en) Method of testing thyrotoxicosis cases
RU2065748C1 (en) Method of treatment of chronic staphyloderma
SU1225574A1 (en) Method of treatment of psoriasis
CN101181253B (en) Chloromycetin eyedrops with long shelf-life and preparation method thereof